Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy
Medicinal Research Reviews · 2024-03 · 44 (2) · 686-706
DOI: 10.1002/med.21994 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 20.11.2023. Verfasst von Naga Rajiv Lakkaniga und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines), Dhanbad, India. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: Science and Engineering Research Board.
Abstract (Originalsprache)
Cancer continues to be a major health concern globally, although the advent of targeted therapy has revolutionized treatment options. Aurora Kinase B is a serine‐threonine kinase that has been explored as an oncology therapeutic target for more than two decades. Aurora Kinase B inhibitors show promising biological results in in‐vitro and in‐vivo experiments. However, there are no inhibitors approved yet for clinical use, primarily because of the side effects associated with Aurora B inhibitors. Several studies demonstrate that Aurora B inhibitors show excellent synergy with various chemotherapeutic agents, radiation therapy, and targeted therapies. This makes it an excellent choice as an adjuvant therapy to first‐line therapies, which greatly improves the therapeutic window and side effect profile. Recent studies indicate the role of Aurora B in some deadly cancers with limited therapeutic options, like triple‐negative breast cancer and glioblastoma. Herein, we review the latest developments in Aurora Kinase B targeted research, with emphasis on its potential as an adjuvant therapy and its role in some of the most difficult‐to‐treat cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines), Dhanbad, India.
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts, USA.
ORCID-Profile: Naga Rajiv Lakkaniga, Hong-Yu Li
Förderung
- Science and Engineering Research Board
Zitieren
APA
Lakkaniga, N. R., Wang, Z., Xiao, Y., Kharbanda, A., Lan, L., & Li, H. Y. (2024). Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy. Medicinal Research Reviews, 44(2), 686-706. https://doi.org/10.1002/med.21994
Vancouver
Lakkaniga NR, Wang Z, Xiao Y, Kharbanda A, Lan L, Li HY. Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy. Medicinal Research Reviews. 2024;44(2):686-706. doi:10.1002/med.21994
BibTeX
@article{Lakkaniga2024,
author = {Lakkaniga, Naga Rajiv and Wang, Zhengyu and Xiao, Yao and Kharbanda, Anupreet and Lan, Li and Li, Hong-Yu},
title = {Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy},
journal = {Medicinal Research Reviews},
year = {2024},
volume = {44},
number = {2},
pages = {686--706},
doi = {10.1002/med.21994}
}
EUVIMED